1367 related articles for article (PubMed ID: 23825154)
21. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
22. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
23. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
24. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant.
Bauer M; Goldstein M; Heylmann D; Kaina B
PLoS One; 2012; 7(6):e39956. PubMed ID: 22768182
[TBL] [Abstract][Full Text] [Related]
25. Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation.
Kobayashi J; Kato A; Ota Y; Ohba R; Komatsu K
Mol Cancer; 2010 Feb; 9():34. PubMed ID: 20144237
[TBL] [Abstract][Full Text] [Related]
26. Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
Choi YE; Park E
J Nutr Biochem; 2015 Dec; 26(12):1442-7. PubMed ID: 26350251
[TBL] [Abstract][Full Text] [Related]
27. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
[TBL] [Abstract][Full Text] [Related]
28. Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.
Fukuda T; Wu W; Okada M; Maeda I; Kojima Y; Hayami R; Miyoshi Y; Tsugawa K; Ohta T
Cancer Sci; 2015 Aug; 106(8):1050-6. PubMed ID: 26053117
[TBL] [Abstract][Full Text] [Related]
29. Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.
Sivanand S; Rhoades S; Jiang Q; Lee JV; Benci J; Zhang J; Yuan S; Viney I; Zhao S; Carrer A; Bennett MJ; Minn AJ; Weljie AM; Greenberg RA; Wellen KE
Mol Cell; 2017 Jul; 67(2):252-265.e6. PubMed ID: 28689661
[TBL] [Abstract][Full Text] [Related]
30. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
31. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.
Luo Y; Leverson JD
Expert Rev Anticancer Ther; 2005 Apr; 5(2):333-42. PubMed ID: 15877529
[TBL] [Abstract][Full Text] [Related]
32. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
33. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
Majuelos-Melguizo J; Rodríguez MI; López-Jiménez L; Rodríguez-Vargas JM; Martí Martín-Consuegra JM; Serrano-Sáenz S; Gavard J; de Almodóvar JM; Oliver FJ
Oncotarget; 2015 Mar; 6(7):4790-803. PubMed ID: 25576921
[TBL] [Abstract][Full Text] [Related]
34. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
36. Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.
Croglio MP; Haake JM; Ryan CP; Wang VS; Lapier J; Schlarbaum JP; Dayani Y; Artuso E; Prandi C; Koltai H; Agama K; Pommier Y; Chen Y; Tricoli L; LaRocque JR; Albanese C; Yarden RI
Oncotarget; 2016 Mar; 7(12):13984-4001. PubMed ID: 26910887
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
38. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
[TBL] [Abstract][Full Text] [Related]
39. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
[TBL] [Abstract][Full Text] [Related]
40. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Luo Q; Li Y; Deng J; Zhang Z
Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
